Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up - PubMed (original) (raw)

Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up

Silke Lassmann et al. Int J Colorectal Dis. 2006 Apr.

Abstract

Aim: Evaluation of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and thymidylate synthase (TS) mRNA levels in formalin-fixed, and paraffin-embedded tissues of patients with colorectal cancer and their prognostic and/or predictive value.

Materials and methods: Total RNA was isolated from microdissected, formalin-fixed, and paraffin-embedded tissues (controls and tumor) and subjected to quantitative RT-PCR (QRT-PCR) in the LightCycler system. Resulting mRNA levels correlated to tumor histology (n=102) and the clinical follow-up in patients treated by resection alone (n=40) and by resection plus adjuvant 5-FU-based chemotherapy (n=52).

Results: Correlation to histopathological parameters revealed a significant association between tumor stage and the TP mRNA level (T and N category and UICC) as well as the TP:DPD (T and N category and UICC) and TS:DPD (T category) ratio. In addition, tumor differentiation was correlated to the TS mRNA level and the TS:DPD ratio. Finally, the TS:DPD ratio was a prognostic marker for overall survival in patients receiving resection alone (p=0.032). Moreover, a high TP:DPD ratio (>8.1; p=0.002) and, marginally, low DPD (<8.2; p=0.05) mRNA levels significantly correlated to disease-free survival.

Conclusion: We present a novel, standardized approach for TP, DPD, and TS mRNA quantification in archival tissue specimens and applied this to a large series of primary colorectal tumors. Correlations to histopathological parameters and clinical follow-up revealed an association of TP, DPD and TS mRNA expression patterns with tumor stage and suggested new prognostic and predictive markers for patients with colorectal cancer.

PubMed Disclaimer

Similar articles

• Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
  Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Häusler P, Becker H, Liersch T. Jakob C, et al. J Pathol. 2004 Dec;204(5):562-8. doi: 10.1002/path.1663. J Pathol. 2004. PMID: 15538739
• Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
  Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C. Ciaparrone M, et al. Oncology. 2006;70(5):366-77. doi: 10.1159/000098110. Epub 2006 Dec 15. Oncology. 2006. PMID: 17179731
• Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
  Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A. Kinoshita M, et al. Anticancer Res. 2007 Mar-Apr;27(2):851-6. Anticancer Res. 2007. PMID: 17465211
• Determinants of prognosis and response to therapy in colorectal cancer.
  Iqbal S, Lenz HJ. Iqbal S, et al. Curr Oncol Rep. 2001 Mar;3(2):102-8. doi: 10.1007/s11912-001-0008-5. Curr Oncol Rep. 2001. PMID: 11177741 Review.

Cited by

• Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.
  Merloni F, Ranallo N, Scortichini L, Giampieri R, Berardi R. Merloni F, et al. Cancer Drug Resist. 2019 Sep 19;2(3):787-802. doi: 10.20517/cdr.2018.006. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582578 Free PMC article. Review.
• Determination of thymidine phosphorylase expression level facilitates recurrence risk stratification in stage II/III colorectal cancer following adjuvant chemotherapy with oral fluoropyrimidines.
  Kugimiya N, Harada E, Suehiro Y, Suga A, Takemoto Y, Hamano K. Kugimiya N, et al. Oncol Lett. 2019 Jun;17(6):5267-5274. doi: 10.3892/ol.2019.10181. Epub 2019 Mar 21. Oncol Lett. 2019. PMID: 31186743 Free PMC article.
• FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
  Mohelnikova-Duchonova B, Melichar B, Soucek P. Mohelnikova-Duchonova B, et al. World J Gastroenterol. 2014 Aug 14;20(30):10316-30. doi: 10.3748/wjg.v20.i30.10316. World J Gastroenterol. 2014. PMID: 25132748 Free PMC article. Review.
• Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.
  O'Connell E, Reynolds IS, Salvucci M, McNamara DA, Burke JP, Prehn JHM. O'Connell E, et al. Pharmacogenomics J. 2021 Aug;21(4):510-519. doi: 10.1038/s41397-021-00229-5. Epub 2021 Mar 17. Pharmacogenomics J. 2021. PMID: 33731881
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
  Panczyk M. Panczyk M. World J Gastroenterol. 2014 Aug 7;20(29):9775-827. doi: 10.3748/wjg.v20.i29.9775. World J Gastroenterol. 2014. PMID: 25110414 Free PMC article. Review.

References

1. 1. Clin Cancer Res. 1999 Aug;5(8):2006-11 - PubMed
2. 1. J Pathol. 1995 Jun;176(2):183-90 - PubMed
3. 1. Cancer Res. 2001 Jul 15;61(14):5505-10 - PubMed
4. 1. Br J Cancer. 2001 Sep 14;85(6):827-30 - PubMed
5. 1. Br J Cancer. 1997;75(6):903-9 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information